ArticleMedicine2026
Associations of the Endothelial Activation and Stress Index with breast cancer prevalence and mortality based on NHANES 2001 to 2018.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the association between the Endothelial Activation and Stress Index (EASIX) and both the prevalence and mortality of breast cancer (BC). Further, it explored the potential mediating role of the Systemic Inflammation Response Index (SIRI). Data were obtained from the National Health and Nutrition Examination Survey 2001 to 2018. Weighted logistic regression models were used to examine the association between EASIX and BC prevalence, while mediation analysis evaluated the contribution of SIRI. Weighted Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for BC mortality, and Kaplan-Meier curves compared survival across EASIX levels. Restricted cubic spline regression assessed linearity, and subgroup analyses tested consistency across covariates. Among 21,329 participants, 593 BC cases were identified. Each 1-unit increase in EASIX was associated with a 39% higher BC risk (odds ratios [ORs] = 1.39, 95% CI: 1.07-1.82, P = .016). Compared with the lowest tertile (T1), the risk was elevated in T2 (OR = 1.61, 95% CI: 1.15-2.26, P = .006) and markedly higher in T3 (OR = 3.07, 95% CI: 2.28-4.14, P < .001). SIRI showed a modest but significant mediating effect, explaining 2.26% of the association (P = .034). No significant interactions were detected. In Cox models, each 1-standard deviation increase in EASIX was associated with a 56% higher risk of all-cause mortality (HR = 1.56, 95% CI: 1.47-1.65, P < .001) and a 104% higher risk among BC patients (HR = 2.04, 95% CI: 1.40-2.98, P < .001). Compared with T1, all-cause mortality increased by 59% in T2 (HR = 1.59) and more than 3-fold in T3 (HR = 3.11). BC-specific mortality was also higher in T3 (HR = 1.16, 95% CI: 1.05-1.27, P = .012). Restricted cubic spline analyses confirmed a linear positive association between EASIX and both BC prevalence and mortality. Elevated EASIX was significantly associated with higher BC prevalence and mortality, partly mediated by systemic inflammation. EASIX may serve as a valuable biomarker for risk assessment and prognosis in BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.